Biogen Idec Inc. (BIIB)
-NasdaqGS 235.24 
2.62(1.13%) 24 May 21:00|After Hours:
:
234.67 0.57 (0.24%) 24 May 21:42
| Prev Close: | 232.62 |
|---|
| Open: | 230.61 |
|---|
| Bid: | 235.24 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 221.41 |
|---|
| Beta: | 1.29 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 229.35 - 235.40 |
|---|
| 52wk Range: | 126.39 - 238.83 |
|---|
| Volume: | 825,879 |
|---|
| Avg Vol (3m): | 1,374,030 |
|---|
| Market Cap: | 55.84b |
|---|
| P/E (ttm): | 37.33 |
|---|
| EPS (ttm): | 6.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Key Statistics
| Forward P/E (1 yr): | 23.74 |
|---|
| P/S (ttm): | 9.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 8.04 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.90 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.56 |
|---|
Business Summary
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.
more 